NCT05030350 Phase 3 Terminated
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD) Study sponsor: VistaGen Therapeutics, Inc. · VTGN
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2022-09-23 Actual
Enrollment · participants 481 Actual
Source updated 2025-10-21 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2025-10-21 · 1 field changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Adverse Events and Other Safety Measures
+ After Measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial